EUVIMEDEUVIMED entdecken
Crossref

Immunoinformatics-based multi-epitope vaccine design using transforming growth factor beta-2 proprotein (TGFB2) for glioblastoma multiforme (GBM): GVac

Deniz Tülümen, Esra Aydemir, Furkan Ayaz

Methods · 2025

DOI: 10.1016/j.ymeth.2025.07.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Methods, 2025. Verfasst von Deniz Tülümen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul 34010, Turkey. Hauptthemen laut MEDLINE: Glioblastoma, Transforming Growth Factor beta2, Cancer Vaccines, Brain Neoplasms. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM), a malignant glioma, is a central nervous system tumor with a high mortality rate in the world. Despite its high mortality rate, there is no effective treatment yet. Classical treatment methods are usually applied to patients, but patients lose their lives in a short time. A strong vaccine or drug that will extend the life of patients has not yet emerged. In this study, various bioinformatic analyses were performed on the Transforming growth factor beta-2 proprotein (TGFB2) belonging to GBM, and a multi-epitope vaccine design was made. These analyses include allergenicity, antigenicity and toxicity tests, various epitope selections, molecular docking, molecular dynamics simulation and immune simulation analyses. As a result of all analyses, a vaccine candidate called GVac was revealed. Gvac is enhanced with an adjuvant called batroxicidin (BatxC), an antimicrobial peptide. While analyses of Gvac generally yield strong results, it offers the potential to be used in various clinical studies if carried forward. With developing technologies, it is now necessary to move away from classical treatment methods and apply to treatment methods that can provide faster and more effective results. This is also the aim of this study. Gvac may offer hope to GBM patients awaiting treatment around the world and the studies need to be carried forward.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTransforming Growth Factor beta2Cancer VaccinesBrain NeoplasmsHumansMolecular Docking SimulationMolecular Dynamics SimulationComputational BiologyEpitopesEpitopes, T-LymphocyteAdjuvants, ImmunologicImmunoinformatics

Stichwörter der Autor:innen

GVacGlioblastoma multiforme (GBM)ImmunoinformaticsIn-SilicoVaccine

Substanzen

Transforming Growth Factor beta2Cancer VaccinesTGFB2 protein, humanEpitopesEpitopes, T-LymphocyteAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Biruni University, Istanbul 34010, Turkey.
  • Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, İstinye University, Istanbul 34010, Turkey. Electronic address: esra.aydemir81@gmail.com.
  • Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, İstinye University, Istanbul 34010, Turkey. Electronic address: furkan1988ayaz@gmail.com.

Zitieren

APA

Tülümen, D., Aydemir, E., & Ayaz, F. (2025). Immunoinformatics-based multi-epitope vaccine design using transforming growth factor beta-2 proprotein (TGFB2) for glioblastoma multiforme (GBM): GVac. Methods. https://doi.org/10.1016/j.ymeth.2025.07.001

Vancouver

Tülümen D, Aydemir E, Ayaz F. Immunoinformatics-based multi-epitope vaccine design using transforming growth factor beta-2 proprotein (TGFB2) for glioblastoma multiforme (GBM): GVac. Methods. 2025. doi:10.1016/j.ymeth.2025.07.001

BibTeX
@article{Tlmen2025,
  author = {Tülümen, Deniz and Aydemir, Esra and Ayaz, Furkan},
  title = {Immunoinformatics-based multi-epitope vaccine design using transforming growth factor beta-2 proprotein (TGFB2) for glioblastoma multiforme (GBM): GVac},
  journal = {Methods},
  year = {2025},
  doi = {10.1016/j.ymeth.2025.07.001}
}
Kostenlos starten →